|
Accueil > Actualité
Pfizer: Commission approves alopecia areata
(CercleFinance.com) - Pfizer has announced that the European Commission (EC) has granted marketing authorisation for LITFULO (ritlecitinib) in the treatment of severe alopecia areata in adults and adolescents aged 12 years and older.
LITFULO, an oral capsule administered once a day, is the first drug authorised by the EC to treat people with severe alopecia areata from the age of 12. Today's approval of LITFULO in Europe is an important milestone for patients as young as 12 with severe hair loss due to alopecia areata, as they now have the opportunity to achieve significant hair regrowth, Pfizer said. Copyright (c) 2023 CercleFinance.com. All rights reserved. |
01/12/2023 17:22
Crédit Agricolel'UE approuve une co-acquisition en Italie 01/12/2023 17:22 Crédit Agricolel'UE approuve une acquisition en Italie 01/12/2023 17:03 Fermentalgla CDC détient moins de 15 % des votes 01/12/2023 16:50 AtosGoldman Sachs détient moins de 5% du capital 01/12/2023 16:27 Boeingla Canada va acquérir 16 appareils P-8A Poseidon 01/12/2023 15:41 Johnson & Johnsonle titre profite d'un avis positif d'UBS Tous les articles sociétés |
